The introduction of a new state of the art cancer treatment technology to South Africa will make more liver and lung tumours treatable, bringing hope to those suffering from these types of cancers.
Prof Krige said that the Accu2i pMTA performed beyond his expectations during the procedure and was easier to handle than the microwave tissue ablation technology that was available previously. The new system ablated tumours more quickly and efficiently than traditional RFA systems, achieving an ablation rate three times faster than RFA.
"The technology provides a completely new dimension to the treatment of patients with complex liver tumours," he pointed out.
The Accu2i pMTA allows larger ablations to be performed which means that this type of therapy will be an option for more liver cancer patients. The technology is also groundbreaking in that it allows patients with more severe disease to be treated, according to Microsulis Medical.
During the Cape Town procedure, which was performed on retired headmaster Mr Rudolf Visser, Prof Krige used the Accu2i pMTA to ablate two 1.5cm and one 2.5cm liver tumours.
Rudolf Visser first had symptoms of his cancer in April 2010, when he suffered severe stomach cramps. A colonoscopy detected the colon cancer and Mr Visser was treated with chemotherapy between May and November 2010, which succeeded in shrinking the liver tumours.
He was then referred to Prof Krige at the UCT PAH for advanced tertiary specialist surgical treatment.
In a four-hour operation on 9 February, Prof Krige removed half of Mr Visser’s large intestine including the primary colon cancer and the lymph nodes. Prof Krige then used intra-operative ultrasound to guide and monitor the microwave ablation of the three secondary cancers in the liver.
Procedure a success